Slough, UK-headquartered Chiltern International, a clinical research organization supplying clinical operations, data management and regulatory affairs services to the pharmaceutical sector, has been ranked in the Deloitte & Touche top-100 fastest-growing companies of 2003.
Chiltern finished 89th on the list, which was contested by over 6,000 businesses with a turnover of L5-L10 million ($8.2-$16.4 million) that had been profitable in their most recent financial year. Chief executive Simon Garnham attributed the firm's success to Chiltern's ability to manage large-scale clinical development programs with "a service that is personal, even to the smallest client and project."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze